Applying Best Evidence to Menopause Management
|
|
- Melvin Hart
- 5 years ago
- Views:
Transcription
1 Applying Best Evidence to Menopause Management Judith Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence UCSF Overview Natural history of menopause Hormone therapy: Risks and Benefits Menopausal symptoms Current role of hormone therapy for menopausal symptoms Non-hormonal treatment of menopausal symptoms Feminine Forever MENOPAUSE IS NOT A DISEASE Dr. Robert Wilson, 1966 Replacing estrogen is like diabetics replacing insulin Women will be much more pleasant to live with and will not become dull and unattractive. Wyeth-Ayerst funded all expenses Page 1
2 Menopause Is A Positive Step Natural History of Menopause Gallup poll 1997: Most middle aged American women welcome menopause as a new and fulfilling life stage. Goal: Support women in achieving a successful transition Average age is 51 Predictors of age at menopause Genetics Family history Ethnicity» Earlier in Latino and later in Japanese American compared to Caucasians Smoking: about two years earlier Reproductive history» Never having children and shorter cycle length associated with earlier menopause Vasomotor Symptoms What do you tell her about when they will go away? Minnie Pause is a 53 year old woman who had her last menstrual period 18 months ago. She is still having hot flashes and awakens at least twice a night with them. She is considering taking estrogen but wants to know how much longer this will last. What do you tell her? Average duration is about 2 years and so they should be gone in about 6 months. Average duration is about 4 years They will never go away Page 2
3 Background Duration of Vasomotor Symptoms Treatment for menopausal symptoms is based on their transitory nature Many clinical guidelines suggest that symptom duration is approximately 2 years Many studies do not follow women more than 2 years Risks and benefits of hormone therapy depend on duration of use Use lowest dose for shortest duration Politi MC et al. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. JGIM 2008:23: Objective: to estimate the natural progression of menopausal symptoms Vasomotor symptoms Results Rigorous meta-analysis included 10 studies with over 35,000 participants Clear definition of vasomotor symptoms Assessed prevalence of symptoms and bothersome symptoms Percent of women with symptoms increased in the two years before the final menstrual period (FMP), peaked one year after the FMP and did not return to premenopausal levels until 8 years after the FMP 50% of women had symptoms during the 4 years after FMP 10% of women had symptoms up to 12 years after FMP Page 3
4 Results: Bothersome Symptoms Duration of Hot Flushes Most prior studies examined populations of older women Newer evidence suggests that these durations might be longer when younger women are included Counseling regarding duration of hot flushes may inform clinical decision making The News Duration of menopausal hot flushes and associated risk factors Freeman, EW et al. Obstetrics and Gynecology, May 2011 Aim: To estimate the duration of moderate-to-severe menopausal hot flushes and identify potential risk factors for hot flush duration. Methods Penn Ovarian Aging Study premenopausal women, ages years (not using hormonal therapy of any type); followed for 13 years Analytic Subsample: 259 women did not report hot flushes at baseline but did experience mod/severe sx during follow-up Measures: validated menopausal symptom list embedded in structured interview, hormones Assessments made at 9-month intervals during study years 0-5, then annually until year 10, every other year until study completion Page 4
5 Menopausal stages Results Premenopause: regular menstrual cycles days long Late premenopause: change of more than 7 days in cycle length Early transition: changes in cycle length of 7 days or more in either direction for 2 consecutive menstrual cycles OR 60 days amenorrhea Late transition: 90 d to 11 months amenorrhea Postmenopause: 12 months or more amenorrhea Soules, et al. Climacteric 2001 Results Hazard Ratio for Likelihood of Hot Flashes Ending Take Home Message Variable HR (95% CI) Menopausal Premenopausal or Late Premenopausal Ref. Early Transition 3.26 ( ) Late Transition or Postmenopausal 5.14 ( ) Age 39 or younger 0.33 ( ) ( ) Ref. 50 or older 1.00 ( ) White Race (Ref: African American) 1.73 ( ) BMI 30 or more (Ref: BMI under 30) 1.94 ( ) Estradiol (mean) 0.82 ( ) In this population-based cohort, median duration of moderate-to-severe hot flushes was 10.2 years! Adding mild hot flushes duration was 11.6 years Younger, thinner, African-American women are likely to have longer hot flush duration Effect of hormone therapy on hot flush duration was not evaluated Clinicians counseling patients about hot flash duration should be mindful that the earlier the hot flashes start, the longer they are likely to last! Page 5
6 Hormone Therapy Hormone therapy is recommended for prevention of which of the following conditions? What have we learned from the Women s Health Initiative? What questions still remain unanswered? What is the current role of HT? Osteoporosis CHD Colorectal Cancer 1 and 3 None of the above Women s Health initiative WHI OUTCOMES Aim was to determine the health risks and benefits of estrogen/progestin in healthy women 16,608 women aged with a uterus Randomized to estrogen/progestin or placebo Primary outcomes CHD (CHD death or non-fatal MI) Invasive breast cancer Writing Group for WHI JAMA 2002 E/P arm stopped at 5.2 years Page 6
7 OTHER WHI PUBLICATIONS HT and the Brain Effects on the brain Effects on CHD Effects on breast cancer Effects on colorectal cancer Effects on osteoporosis Effects on venous thrombosis Effects on gallbladder disease Effects on incontinence Effects of estrogen alone WHI Memory Study Subgroup of WHI Slight increase in dementia in hormone therapy group» Absolute number of cases was small Greater decrease in modified mini mental status exam in hormone therapy group Rapp, JAMA 2003; Shumaker, JAMA 2003 Increase in stroke in HT group 1.8% vs 1.3% Hazard ratio 1.31 (1.02, 1.68) Wassertheil-Stoller, 2003 HT AND CHD: WHI BREAST CANCER OUTCOMES: WHI Final results of the effects of estrogen and progestin on CHD outcomes HT users had a hazard ratio for CHD higher than non-users HR 1.24 (95% C.I. 1.00, 1.54) Risk was highest in the first year HR 1.81 (95% C.I. 1.09, 3.01) Manson, NEJM 2003 Since the WHI, use of hormone therapy (HT) in the U.S. has decreased Breast cancer incidence has also decreased in the U.S. What is the long term impact of HT on breast cancer? Page 7
8 Adherent Participants in WHI: Invasive Breast Cancers by Group Figure 2. Incidence of Invasive Breast Cancer in the WHI Clinical Trial Chlebowski RT et al: JAMA 2003; 289: Chlebowski, R. T. et al. JAMA 2010;304: Copyright restrictions may apply. Breast Cancer Outcomes: WHI OSTEOPOSIS RESULTS: WHI Combined E+P therapy increases the cumulative risk of invasive breast cancer, and diagnosed cancers are more likely to be node-positive This risk becomes evident within about 4.7 years of randomization and is persistent through a total of 11 years of follow-up There were more breast cancer deaths in the combined E+P group Chlebowski JAMA % of placebo treated women compared with 8.6% of estrogen treated women had a fracture Hazard ratio 0.76 (95% C.I. 0.69, 0.83) Effects did not differ by age, BMI, smoking status, history of falls, family history of osteoporosis, past use of hormone therapy or BMD No global benefit even in high risk women» Cauley, JAMA 2003 Page 8
9 COLORECTAL CANCER: WHI VTE Outcomes: WHI Reduced rate of colorectal cancer in hormone therapy users Hazard ratio 0.56; 95% C.I. 0.38, 0.81) Invasive cancers in the hormone group had a greater number of positive lymph nodes and were more advanced» Chlebowski NEJM 2004 Risk increased overall in HT users HR 2.06 (95% C.I. 1.57, 2.70) Risk higher in older women HR 4.28 (95% C.I. 2.38, 7.72) for women aged HR 7.46 (95% C.I. 4.32, 14.38) for women aged Risk higher in obese women HR 3.8 (95% C.I. 2.08, 6.94) for overweight HR 5.61 (95% C.I. 3.12, 10.11) for obese Factor V Leiden increased HT associated risk Cushman, JAMA 2004 Gallbladder Disease: WHI Urinary Incontinence: WHI Increased risk of any gallbladder disease or surgery in hormone therapy users HR 1.67 (95% C.I , 2.06) in estrogen users HR 1.59 (95% C.I. 1.28, 1.97) in estrogen/progestin users Increased risk of cholecystitis, cholelithiasis, and cholecystectomy in both groups NNH 323 for CEE 500 for E plus P Cirillo JAMA 2005 HT has long been thought to relieve the symptoms of urinary incontinence HT increased the incidence of all types of urinary incontinence at 1 year among women who were continent at baseline Among women with UI at baseline, frequency worsened in hormone users Did not assess vaginal estrogens» Hendrix JAMA 2005 Page 9
10 HT and Quality of Life WHI: Estrogen Alone In the WHI there were small improvements in quality of life among women who had vasomotor symptoms Hormone therapy is associated with improvement in some quality of life measures in women with vasomotor symptoms and may improve sexual function and vitality Hess, 2008; Welton, ,739 postmenopausal women aged with prior hysterectomy Intervention phase ended early after reviewing data through November, 2003 Average follow-up 6.8 years WHI: Estrogen Alone WHI: Outcomes after Stopping CEE Non-significant reduction in breast cancer RH 0.77 (95% C.I. 0.59, 1.01) No reduction in colon cancer RH 1.08 (95% C.I. 0.75, 1.55) Non-significant increase in pulmonary embolism RH 1.34 (95% C.I. 0.87, 2.06) Lower risk of fractures RH 0.70 (95% C.I. 0.63, 0.79) Increased risk of stroke Global index not consistent with harm RH 1.01 (95% C.I. 0.91, 1.12) Follow-up after treatment with CEE CEE use median 5.9 years Mean follow-up 10.7 years No increase or decrease in CHD, DVT, stroke, hip fracture, CRC or total mortality Decreased risk of breast cancer continued» LaCroix, JAMA 2011 Page 10
11 Adherent Participants In WHI: Invasive Breast Cancers In E Alone Study WHI OUTCOMES (E +P) 23% reduction in BC over 11 years with 6 years of CEE in women without a uterus. Recently updated from all WHI studies Treat 10,000 women for a year 9 strokes 9 P.E.s 12 DVTs 8 invasive breast cancers 5 more lung cancer deaths 6 fewer hip fractures 46 fewer fractures 22 cases of dementia 20 cases of gall bladder disease 872 cases or urinary incontinence Nelson et al. Ann Intern Med 2012:157: LaCroix, JAMA, 2011 WHI Outcomes (E alone) CLINICAL QUESTIONS Recently updated from all WHI studies Treat 10,000 women for a year 56 fewer fractures 8 fewer invasive breast cancers 2 fewer deaths 11 more strokes 7 more DVTs 33 more cases of gallbaldder disease 1,271 more cases of urinary incontinence What about other estrogen/progestin combinations? What about younger women? Does it matter when you start HT? What about symptomatic treatment? Nelson et al. Ann Inern Med 2012: 157: Page 11
12 Transdermal Estrogen Age at Initiation: Background Transdermal estrogen avoids hepatic first pass metabolism Transdermal estrogen may be associated with a lower risk of VTE Canonico, 2007 Transdermal estrogen associated with a lower risk of stroke Renoux BMJ 2010 RCTs and observational studies have found differing results of the effect of HT on CHD Observational studies have generally shown benefit Women in observational studies are generally younger and started HT closer to the time of menopause Mean age of women in the WHI was 63 Hormone Therapy in Younger Women Hormone Therapy in Younger Women Secondary analysis of WHI data Combined the women who received E plus P with the women who received E alone Risk for CHD with HT increased with increasing time since menopause < 10 years: 0.76 (0.50, 1.16) years: 1.10 (0.84, 1.45) 20 or more years 1.28 (1.03, 1.58)» P for trend=0.02 Roussow JAMA 2007 Hormone therapy increased risk of stroke regardless of age or years since menopause» HR 1.32 (1.12, 1.56) Non-significant trend for the effects of hormone therapy on total mortality to be more favorable in younger women Page 12
13 Estrogen Alone: Results by Age at Enrollment Take home message Statistically significant age interactions for CEE group greater safety and benefit for women in 50s potential harm among older women Timing of HT initiation relative to age or menopause onset may influence CHD risk Less underlying atherosclerosis in younger women? Clinicians should counsel women differently based on age and hysterectomy status Unlikely to change current recommendations for HT use Statistically significant age interactions (greater safety and benefit for younger women, potential harm among older women) were shown for: CHD, total MI, colorectal CA, total mortality and the global index. La Croix et al. JAMA 2011 Danish Osteoporosis Study: CV Outcomes 1006 healthy recently menopausal women aged Open-label randomization to triphasic estradiol/norethisterone or placebo (hysterectomy: treatment with estradiol alone) for 10 years Outcomes: Composite outcome of death or admission for myocardial infarction or heart failure Individual components of primary endpoint, admission for stroke Schierbeck et al. BMJ 2012; 345:e6409. Results WHI: mean age 63 WHI: 13% with increased lipids WHI: 36% with HTN WHI: 4% with DM Page 13
14 Primary endpoint and mortality for hormone replacement therapy Take Home Messages The findings from this study substantiate the timing theory but Different type and dose of estrogen used Underpowered to determine effect of Estrogen monotherapy Unclear if primary composite outcome was prespecified Minimal risk associated with therapy but Likely underpowered to detect differences in DVT/PE, CVA, and possibly breast CA Overall: reassured about using HT in symptomatic healthy menopausal women, but would not prescribe for primary prevention Schierbeck L L et al. BMJ 2012;345:bmj.e6409 Menopausal Symptoms: Prevalence Menopausal Symptoms Hot flushes (50% or more)» Often with perspiration Night sweats (50% or more) Sleep disturbance (40-60%) Page 14
15 OTHER SYMPTOMS Other symptoms happen at the time of menopause but are less clearly related to menopause Mood changes Cognition Changes in sexual function Urinary complaints Treatment of Menopausal Symptoms What do you most commonly recommend for the treatment of severe vasomotor symptoms? HT for Symptomatic Relief Estrogen SSRI Venlafaxine Clonidine Gabapentin Lifestyle changes and/or complementary therapy Any form of estrogen is highly effective Generally can be taken for a few years and gradually stopped A progestin should be added for women with a uterus Therapy can be tailored to a woman s preference Decision should be made SEPARATELY from decision for disease prevention Page 15
16 Effective Dose Equivalents Lower dose hormone therapy Dose that stops hot flashes in 80% of women 1 mg micronized 17 beta estradiol 50mcg/day transdermal 17 beta-estradiol mg conjugated equine estrogens 1.25 mg piperazine estrone sulfate Lower doses have been effective in some trials Estimates of efficacy after 12 weeks 38% placebo 63% low dose estrogen 83% standard dose estrogen Lower doses may take longer for maximal symptom relief 12 weeks vs 4-8 weeks Less bleeding and breast tenderness and may require less progestin» Ettinger, Am J Med 2005 QUESTION QUESTION Estee Jenn is a 60 year old woman who has been on HT for 10 years. You have been trying to encourage her to stop it for a while but she has not wanted to do it. Her best friend has recently developed breast cancer; she has now decided to stop, and wants your advice on the best way to do it. What do you recommend? Taper by decreasing the daily dose over 6-12 months Taper by decreasing the number of days a week HT is used over 6-12 months Just stop Page 16
17 Discontinuing hormone therapy Progestins Symptoms will recur in up to 25% of women with stopping therapy Unclear if it is best to stop cold turkey or to taper Taper can be by daily dose or number of days per week Taper until mild symptoms Maintain that dose until symptoms resolve Concern about VTE and breast cancer risk High doses Oral megestrol (20-80 mg) has shown efficacy Some weight gain Goodwin J Clin Oncology 2008 High dose depo-mpa (400 mg) is also effective Compared with venlafaxine Loprinzi J Clin Oncol 2006 QUESTION OTHER DRUG TREATMENTS Estee has a resumption of her hot flashes after she stops her estrogen. What pharmacologic alternative do you suggest? Paroxitene Escitalopram Venlafaxine Clonidine Gabapentin SSRIs Venlafaxine Desvenlafaxine Clonidine 50-67% reduction in hot flash frequency with these regimens Placebo effects generally large Generally less than estrogen Page 17
18 Paroxitene Escitalopram Paroxitene CR led to a significant decrease in hot flash score 62% in 12.5 mg group 65% in 25 mg group 38% in placebo group Avoid in women receiving tamoxifen Decreases active metabolite of tamoxifen Cytochrome P450 CYP2D6 Recent study of the efficacy of escitalopram Reduction in hot flash frequency 55% in escitalopram group 36% in placebo group Effective in African American and Caucasian women Effective regardless of coexisting anxiety or depression» Freeman, JAMA 2011 Venlafaxine Desvenlafaxine Significant reduction in hot flashes 61% vs 27% in placebo (p<0.01) 150 mg no more effective than 75 mg Lopinzi, Lancet 2000 Industry sponsored trial of metabolite of venlafaxine 700 women with severe hot flashes 64% reduction in hot flashes at 12 weeks Vs 51% with placebo Hot flashes less severe in desvenlafaxine group Not currently FDA approved for this indication Speroff, 2008 Page 18
19 Clonidine and Gabapentin Alternatives for treatment of hot flushes Clonidine Start with 0.1 mg/day transdermal patch 40% reduction in hot flashes Side effects can be limiting Gabapentin 45% reduction in hot flashes vs placebo (29%) 900 mg a day more effective than placebo mg at bedtime may help with hot flashes that awaken patients from sleep Treatment Dosage (mg/day) Efficacy (vs placebo) Estrogen CEE 80% vs 20-30% Paroxitene 12.5 or 25 62% vs 38% Escitalopram 10 to 20 55% vs 36% Venlafaxine % vs 27% Venlafaxine 75 or % vs 27% Desvenlafaxine % vs 51% Clonidine % vs 20% Question Background Estee is tired of medications and would like to try an herbal therapy for treatment of her hot flashes. What treatment do you recommend? Evening primrose Ginseng Dietary soy Wild yam None of the above Soy products have been proposed to provide comparable benefits to estrogen for treating menopausal symptoms, without the risks Epidemiologic studies on Asian women suggest that soy-containing foods are of benefit to the skeleton Limited by short duration, low dose of soy isoflavones, few participants Rapid bone loss occurs during the first 2 years of menopause Page 19
20 SPARE Study: Soy isoflavones Results SPARE study (Soy Phytoestrogens As Replacement Estrogen) parallel group, placebo controlled, double blind trial 248 women (early menopause) were randomly assigned to receive 200mg soy isoflavones or placebo Measures: BMD change Menopausal symptoms Vaginal Maturation Lipids and thyrotropin Assessed at baseline, 12 mo, & 24 mo No significant differences between soy and placebo group: Spinal BMD Total hip BMD Femoral neck BMD NTx (N-telopeptide type I bone collagen) Subgroup analyses by: race, BMI, estradiol, 25-OH Vit D Women with low 25-OH vit D at baseline soy group had lower decrease in spinal BMD than placebo Rate of hot flashes actually increased in soy isoflavone group (48% vs 32%: p=0.02) Summary Of Herbal Evidence Lifestyle and Complementary Modalities Evidence: no benefit Red Clover Dong quai Ginseng Evening primrose Wild yam Vitamin E Acupuncture Evidence mixed Soy Black cohosh No data Chasteberry Licorice Cooling body temperature Exercise Avoiding hot and spicy foods Relaxing therapies Yoga, massage, mediation, slow breathing, baths Mind-body therapies Relaxation, biofeedback, paced respiration, hypnosis NAMS Some evidence that weight loss is beneficial Page 20
21 Hot Flash: Self Help - Be Cool! Relaxation Keep house cool Avoid caffeine, alcohol, spicy foods, hot drinks Dress in layers, cotton Light bed linens Use fan, cool drinks Exercise Relaxation therapy 73% reduction HF Diaphragmatic breathing Simple deep breathing when sense HF > 50% reduction HF Wijma, 1997 Freedman 1995 Recommendations Guidelines for Hormone Therapy Use USPSTF: Harmful effects are likely to exceed the chronic disease prevention benefits in most women ACOG, AHA, and Canadian Task Force recommend against use of HT for prevention of chronic disease NAMS 2012: When alternative therapies not appropriate, extended use of HT appropriate for women at high risk of fracture Page 21
22 NAMS 2012 Recommendations Summary Focuses on emerging differences between ET and EPT as varying ages and time intervals since menopause Individualization in decision to use HT :consider individual health, personal risk factors and quality of life priorities ET has a more favorable risk benefit profile which allows for more flexibility in duration of use EPT associated with an increased risk of breast cancer incidence and mortality after 3-5 years Average duration of menopausal symptoms is approximately 4 years but seems to be longer in younger women Estrogen either alone or with a progestin is not recommended for chronic disease prevention in postmenopausal women Risks and benefits may differ in older and younger women Premature menopause: HT until median age of natural menopause and then reassess Menopause 2012: Summary Estrogen works best for menopausal symptoms Use lowest dose for shortest duration Best method for discontinuation is not known Start with lifestyle modifications and nonprescription remedies Other drug alternatives include venlafaxine, desvenlafaxine, paroxitene, escitalopram, gabapentin, and clonidine Questions? Page 22
Applying Best Evidence to Menopause Management MENOPAUSE IS NOT A DISEASE. Overview. Feminine Forever. Page 1
Applying Best Evidence to Menopause Management Judith Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence UCSF Overview Natural history of menopause Hormone therapy:
More informationApplying Best Evidence to Menopause Management MENOPAUSE IS NOT A DISEASE. Overview. Feminine Forever. Page 1
Applying Best Evidence to Menopause Management Judith Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence UCSF Overview Natural history of menopause Hormone therapy:
More informationMENOPAUSE IS NOT A DISEASE
Clinical Dilemmas in Menopause Management: A Case Based Approach Judith M.E. Walsh, MD, MPH Professor of Medicine UCSF Women s Health Center of Excellence Conflicts of Interest: None Overview Natural history
More informationGuidelines for Menopause Management
Guidelines for Menopause Management Judith M.E. Walsh, MD, MPH Professor of Medicine UCSF Women s Health Center of Excellence Conflicts of Interest: None Overview Natural history of menopause Hormone therapy:
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationOVERVIEW WOMEN S HEALTH: YEAR IN REVIEW
OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW Judith Walsh, MD, MPH Professor of Medicine UCSF Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature from March, 2008 through
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationOVERVIEW OF MENOPAUSE
OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationManagement of Perimenopausal symptoms
Management of Perimenopausal symptoms Serge Rozenberg CHU St Pierre Université libre de Bruxelles Belgium serge_rozenberg@stpierre-bru.be serge.rozenberg@skynet.be Conflict of interest & Disclosure Conflicts
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationMenopausal Management: What Has Changed?
Menopausal Management: What Has Changed? Julia V. Johnson, M.D. Professor and Chair, OB/GYN University of Massachusetts Medical School UMass Memorial Medical Center Conflicts of Interest None Learning
More informationIssues in Cancer Survivorship. Larissa A. Korde, MD, MPH June 26, 2010
Issues in Cancer Survivorship Larissa A. Korde, MD, MPH June 26, 2010 Estimated US Cancer Cases in Women: 2006-2008 CA Cancer J Clin 2006; 56:106-130; CA Cancer J Clin 2008;58:71 96. Relative Survival*
More informationCase Presentation. Learning Objectives. Case Presentation. Case Presentation
Learning Objectives To apply up to date information about the natural history of menopause to improve the care of individual women To counsel women about the risks and benefits of systemic hormone therapy
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationJames H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
More informationPrior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD
Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,
More informationFlashpoint: Regulating Your Body s Temperature. Presented by: Shari M. Lawson, MD MBA Date Presented: November 1,
Flashpoint: Regulating Your Body s Temperature Presented by: Shari M. Lawson, MD MBA Date Presented: November 1, 2014 1 Disclosures None 2 Objectives Today s discussion will cover How body temperature
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationPotential dangers of hormone replacement therapy in women at high risk
ESC meeting, Stockholm, August 30, 16.30-18.00, 2010 Potential dangers of hormone replacement therapy in women at high risk Karin Schenck-Gustafsson MD, PhD, FESC Professor, Chief consultant Department
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationMENOPAUSAL HORMONE THERAPY 2016
MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.
More information2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK
2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK WHI the only large, long-term RCT of HT in women aged 50 to 79 years, Drug trail
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationOB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.
OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,
More informationMs. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
More informationMenopause Symptoms and Management: After Breast Cancer
Menopause Symptoms and Management: After Breast Cancer An Educational Webinar for Patients and their Caregivers Wen Shen, MD, MPH Division of Gynecologic Specialties July 27, 2018 1 Disclosure I have a
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationWhat s New in Menopause Management. Objectives
What s New in Menopause Management Leslee L. Subak, MD Professor of Obstetrics, Gynecology & Reproductive Science University of California, San Francisco Objectives Define the menopause transition Review
More informationManagement of Menopausal Symptoms
Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More informationNorth American Menopause Society (NAMS)
North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College
More informationFinancial Conflicts of Interest
Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine
More informationGary Elkins, PhD., ABPP
Gary Elkins, PhD., ABPP *What are Hot Flashes? *Hormone Replacement Therapy *Alternate Treatment Options *Clinical Hypnosis? *Methods *Preliminary Results *Conclusions & Future Directions *Over 66% of
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationVenous thromboembolism 5 years of use *p-value <.05. Net bad events +2.0* +0.6
Management of Menopause: Should New Data Change Our Practice? Mary S. Beattie, MD, MAS Associate Professor of Medicine UCSF Women s Health, Primary Care Director of Clinical Research, UCSF Cancer Risk
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More informationSupplementary Online Content
Supplementary Online Content Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for
More informationHT: Where do we stand after WHI?
HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationBefore you prescribe
Initiating hormone replacement therapy (HRT) / menopausal hormone therapy (MHT) Dr Sonia Davison Jean Hailes Consultant Endocrinologist Before you prescribe Ensure there are no contraindications to HRT/MHT
More informationWHI, Nurses and SWANs: Do Big Clinical Trials Inform Personalized Care? KIRTLY PARKER JONES MD
WHI, Nurses and SWANs: Do Big Clinical Trials Inform Personalized Care? KIRTLY PARKER JONES MD Conflicts? No financial conflicts of interest (Dr. Jones is a post menopausal female reproductive endocrinologist
More informationWhat is the menopause?
Information for you Alternatives to hormone replacement therapy for symptoms of the menopause Published in December 2011 This information is for you if you are considering alternatives to hormone replacement
More informationNon hormonal medical treatment of vasomotor symptoms
Non hormonal medical treatment of vasomotor symptoms Caroline Antoine Menopause Clinic Department of Gynaecology and Obstetrics CHU Saint-Pierre Belgian Menopause Society Symposium November 14, 2015 No
More informationDINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC
DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD
More informationMenopause and Post Gynecological Reproductive Care
Menopause and Post Gynecological Reproductive Care Nguyet-Cam Vu Lam, MD, FAAFP Associate Program Director St. Luke s Family Medicine Residency 1 Disclosure Dr. Nguyet-Cam Vu Lam has no conflict of interest,
More informationThis information can be found by going to Hot Flashes
Winsor Pilates - Official Site Reach physical and mental health while sculpting your... www.winsorpilates.com ML Speakers Group -Women's Health Today Book an exciting speaker to make your event special.
More informationWhat's New in Menopause Management
Annual Review of Family Medicine December 10, 2015 San Francisco, CA What's New in Menopause Management Michael Policar, MD, MPH Clinical Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine
More informationA Practitioner s Toolkit for the Management of the Menopause
Medicine, Nursing and Health Sciences A Practitioner s Toolkit for the Management of the Menopause Developed by the Women s Health Research Program School of Public Health and Preventive Medicine Monash
More informationUPDATE: Women s Health Issues
UPDATE: Women s Health Issues Renee B. Alexis, MD, MBA, MPH, FACOG Associate Professor Department of OBGYN Kiran C. Patel College of Osteopathic Medicine Disclosure of Conflicts of Interest I have no financial
More informationMenopause and HIV. Together, we can change the course of the HIV epidemic one woman at a time.
Menopause and HIV Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Menopause? Menopause: Point in time when a woman's menstrual periods
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More informationHRT & Menopause Where Do We Stand Now?
HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by
More informationAppendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
More informationWHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
More informationDisclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
More informationMenopause: diagnosis and management NICE guideline NG23. Published November 2015
Menopause: diagnosis and management NICE guideline NG23 Published November 2015 1 Full title: Menopause : diagnosis and management Available at: http://www.nice.org.uk/guidance/ng23 Guideline published
More informationTHE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY
Annu. Rev. Public Health 2005. 26:115 40 doi: 10.1146/annurev.publhealth.26.021304.144637 Copyright c 2005 by Annual Reviews. All rights reserved THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY Elizabeth
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationCLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationMenopause Matters. Equity Office Staff Seminar 14 November 2018
Menopause Matters Equity Office Staff Seminar 14 November 2018 1 What to expect at menopause How to manage symptoms Support at work Dr Janice Brown Medical lead, The University of Auckland NZ representative,
More informationBenton Franklin County Medical Society 31st Annual CME Seminar
Management of Current HT/ET and SERM Recommendations Benton Franklin County Medical Society 31st Annual CME Seminar February 21, 2015 Kennewick, Washington Spokane steoporosis Dr. Lynn Kohlmeier Lynn Kohlmeier,
More information22/09/2014. Menopause Management. Menopause. Menopause symptoms
Menopause Management Dr Sonia Davison Jean Hailes for Women s Health Menopause Time of last menstrual period - average age 51 Premature Menopause: occurs before age 40 Perimenopause (menopause transition):
More informationWHI Form 55 Estrogen-Alone Survey Ver. 2
Date Received: - - (M/D/Y) Reviewed By: - Affix label here- Clinical Center/ID: - - First Name M.I. Last Name Contact Type: Phone Visit Type: Form Administration: Mail Semi-Annual # Self 3 Visit 3 Annual
More informationCoronary Heart Disease in Women Go Red for Women
Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men
More informationQuality of Life. Local Therapy of UG Atrophy. Key Message #1 24/05/2018. Perception of Fears/Problems at Menopause
Disclosure Menopause Webinar May 24, 2018 Gillian Graves Obs Gyn Dalhousie University Retired No Advisory Boards or other industry relations Guidelines Oversight Committee SOGC Royal College Subspecialty
More informationMenopause - a summary of management
Page 1 of 5 Menopause - a summary of management Original article by: May Su Resources Menopause treatment algorithm The Jean Hales Foundation for women's heath. Menopause, a treatment algorithm. (Australian
More informationAll medications are a double-edged sword with risks
Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: 10.1097/gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone
More informationPearls for Menopause Management: I m ready: now what?
Pearls for Menopause Management: I m ready: now what? Friday November 13, 2015 Susan Goldstein MD CCFP FCFP NCMP Assistant Professor Department of Family and Community Medicine University of Toronto Menarche
More informationHow HRT Hurts the Heart
How HRT Hurts the Heart Coronary artery disease (CAD) is a killer and recent studies have come up with evidence that HRT might have a role in increasing CAD among women. Why? Zaheer Lakhani, MD, FRCP For
More informationHormone replacement therapy in postmenopausal women
The American Journal of Surgery 188 (2004) 136 149 Review Hormone replacement therapy in postmenopausal women Edgar D. Staren, M.D., Ph.D., M.B.A.*, Shuab Omer, M.D. Department of Surgery, Medical College
More informationOverview: Identifying Candidates and Tailoring Treatment. Disclosures 10/6/2014. Vasomotor Symptoms. VMS in Postmenopausal Women
Overview: Identifying Candidates and Tailoring Treatment Risa Kagan, MD, FACOG, CCD, NCMP Clinical Professor, Department of Ob-Gyn, UCSF East Bay Physicians Medical Group Sutter Foundation, Berkeley, CA
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationThe Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationPostmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationBy J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University
By J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University Cessation of menstruation as a result of the aging process of or surgical removal of the ovaries; change
More informationHealth Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators 1 Background: WHI Hormone Program Design YES N= 10,739 Conjugated equine estrogen
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationNavigating the Change: Leading Patients Through Menopause
4:30pm - 5:30pm: Breakout 5 - Women s Health Option A: Navigating the Change: Leading Patients Through Menopause ACPE UAN 0107-0000-10-025-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based Program
More informationWOMEN S HEALTH: A REVIEW OF THIS YEAR S MOST IMPORTANT PAPERS OVERVIEW BUT NOT. TOPICS 8/14/2009. Judith Walsh, MD, MPH Professor of Medicine UCSF
WOMEN S HEALTH: A REVIEW OF THIS YEAR S MOST IMPORTANT PAPERS Judith Walsh, MD, MPH Professor of Medicine UCSF OVERVIEW Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationMenopausal Hormone Therapy
V FORUM on WOMEN, HEALTH, and GENDER Madrid, October 14-15, 2008 Menopausal Hormone Therapy The Women s Health Initiative (WHI) randomized, placebo-controlled trials Marcia L. Stefanick, Ph.D. Professor
More informationMENOPAUSE. Women in Midlife: Menopause & Osteoporosis. Outline for Menopause. STRAW Stages of the Menopausal Transition-NAMS, /29/2012
Women in Midlife: Menopause & Osteoporosis Lisa Ward, MD, MScPH, MS UCSF CME Conference March 23rd, 2012 MENOPAUSE Outline for Menopause Definitions Summary of the Evidence Current Guidelines Management
More informationPrimary Care of the Breast Cancer Survivor. Case Presentation. Case Presentation (cont) Case Presentation (cont) Breast Cancer
Primary Care of the Breast Cancer Survivor Janet P. Pregler, MD Professor of Clinical Medicine Director, Iris Cantor UCLA Women s Health Center Case Presentation B.C. is a 58 year-old African American
More informationUpdate in Women s Health Year In Review
Update in Women s Health Year In Review Judith Walsh MD, MPH Professor of Medicine Division of General Internal Medicine And Epidemiology and Biostatistics I have no disclosures Disclosures 1 Plan for
More informationRALOXIFENE Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA Is the request for the prevention (risk reduction) of breast cancer?
Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA 16917 GUIDELINES FOR USE 1. Is the request for the prevention (risk reduction) of breast cancer? If yes, continue to #2. If no, approve by HICL
More informationDifference between vagifem and yuvafem
Difference between vagifem and yuvafem Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. Estrogen-alone
More informationThe Estrogen Question
The Estrogen Question Hormone Therapy still offers the best relief for menopausal symptoms. Is it right for you? When 49-year-old Lee Ann Dodson heard the news that the Women's Health Initiative (WHI)
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More information